Skip to content

Study on early intelligence diagnosis technology and comprehensive intervention model of children and adolescents with bipolar disorder

Study on early intelligence diagnosis technology and comprehensive intervention model of children and adolescents with bipolar disorder

Status
Active, not recruiting
Phases
Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400084651
Enrollment
Unknown
Registered
2024-05-22
Start date
2022-11-10
Completion date
Unknown
Last updated
2024-05-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bipolar disorder

Interventions

Drug plus probiotics treatment group:probiotics
Medicine combined with physical therapy group:Repetitive transcranial magnetic stimulation
Healthy control group:none
Monotherapy group:Psychotropic drug

Sponsors

The Affiliated Brain Hospital Of Guangzhou Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
8 Years to 18 Years

Inclusion criteria

Inclusion criteria: 1. The age is between 8-18 years old; Han nationality; Right handed; No history of electroconvulsive therapy within three months; 2. PBD group: meet the requirements of MRI examination; It conforms to the diagnostic criteria of bipolar affective disorder in the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV-TR) of the United States. The number of previous major depressive episodes does not exceed two, and the total time of taking antidepressants in the past is less than 3 months. 3. Healthy control group: according to the principle of matching nearby (age, sex and education level); No history of mental illness, which does not meet the diagnosis of any mental illness in DSM-IV-TR; No family history of mental illness. 4. No history of nervous system disease or major somatic disease; No history of alcohol and drug abuse or dependence 5. At least one adult person shall take care of all participants, record the drug intake of patients, monitor the compliance of patients and timely find adverse drug reactions; 6. Obtain the written informed consent of the patient. If the patient is incapacitated during the onset period, the written informed consent of his/her legal guardian is required.

Exclusion criteria

Exclusion criteria: (1) Schizoaffective psychosis, mood disorder, mental retardation, generalized developmental disorder, delirium, dementia, memory disorder or other cognitive disorders meeting DSM-V diagnostic criteria; (2) People with severe unstable somatic diseases; Diagnosed diabetes, thyroid disease, hypertension, heart disease, etc; (3) MRI contraindications (such as metal implants, pacemakers and severe claustrophobia); (4) Pregnancy (urine human chorionic gonadotropin screening), lactation or intervention do not accept effective contraceptive measures; (5) Substance dependence (except nicotine addiction); (6) Those who have used ECT for six months before enrollment; (7) Serious suicide attempts or serious excitement; (8) There is sufficient evidence to show that the patient has poor efficacy on the two antipsychotic drugs with different mechanisms (the criteria for poor efficacy are full dose, full course of treatment, and full compliance, and the patient still has serious mental symptoms); (9) Patients with contraindications to the antipsychotic drugs recommended by this topic; (10) Previous head injury with consciousness disorder for more than 5 minutes; (11) The participants were unable to cooperate with the conditions proposed by the researchers; (12) Those who cannot take medicine according to the doctor's advice or have no guardian;

Design outcomes

Primary

MeasureTime frame
Hamilton Depression Scale;Positive and Negative Syndrome Scale;young manic rating scale;

Secondary

MeasureTime frame
weight;

Countries

china

Contacts

Public ContactLu Xiaobing

The Affiliated Brain Hospital Of Guangzhou Medical University

13688876346@139.com+86 136 8887 6346

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026